Observational studyCancer medicine2025

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Yian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.